London: British drug development firm Vectura Group Plc said on 23 April 2007 that a phase two clinical study on its inhaled erectile dysfunction (ED) product had been successful.
“It is particularly encouraging that such performance has now been demonstrated in ED patients across two separate clinical studies,” Alan Riley, the principal investigator of the study, said. Vectura said in the second double-blind placebo-controlled trial of around 600 patients, VR004 improved erectile performance, with a rapid onset of action, and was well-tolerated.
“Most interestingly, the company confirmed a rapid onset of action which was previously seen in its other study ... We remain strong buyers of Vectura,” Bridgewell Analyst Elizabeth Klein said.
Vectura plans to outlicense its sexual dysfunction programme and Klein said, following these tests, she would expect it to be able to do so within the next year.
Shares in Vectura were up 1.4% at 88-1/2 pence in early trade, valuing the group at around 278 million pounds (Rs2,316 crore).
ED, which affects more than 50 million men in the United States and European Union, is defined as the consistent inability to achieve and maintain an erection adequate for satisfactory sexual function.